Pfizer Ventures

Profile

Pfizer Ventures (PV), the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. PV seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.

With a $600M capital commitment from Pfizer for private investments in 2018, PV invests in private companies at all stages of development, with a strong focus on early stage opportunities. Other investments, including start-ups and spinouts, will also be considered. We actively work with our current portfolio companies throughout their growth cycles, contributing strategic guidance in addition to our capital and providing access to internal Pfizer expertise, whenever appropriate. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation commensurate with our investment.

INVESTMENT STRATEGY
Primarily focused on potentially transformative therapeutics, with an emphasis on Pfizer's core therapeutic areas (Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines).
Focus also includes neuroscience investments, following Pfizer's decision to continue advancing research in this critical area of unmet medical need through a venture capital strategy.
Will also consider platform technologies, diagnostics, drug delivery, pharmaceutical services and other technologies that have the potential to transform drug discovery and development.
KEY POINTS
Active investor, working with management to develop product strategy and build shareholder value.
Bring Pfizer pedigree and perspective to our portfolio companies, with the potential to utilize the network and expertise of Pfizer.
Streamlined approval process for investment decisions.
Potential for Pfizer business development relationship whenever appropriate.